返回 Agenda
Session 2 Track A: Clinical Experience with Immune-Targeting Oligonucleotides and MicroRNAs
Session Chair(s)
Arthur M. Krieg, MD
CEO and CSO
Checkmate Pharmaceuticals, United States
Daniela Verthelyi, MD, PhD
Chief, Laboratory of Immunology, OBP, OPQ, CDER
FDA, United States
Therapeutic oligonucleotides offer a remarkable breadth of mechanisms and applications aside from inducing the cleavage of a target mRNA. This session explores a few of these including activating anti-tumor immunity with CpG DNA through TLR9 or with RNA and regulating the function of microRNAs.
Learning Objective : At the conclusion of this session, participants should be able to:- Describe the immune pathways that can detect foreign RNA and DNA
- Recognize how immune activation by DNA and RNA can trigger anti-tumor immunity
- Understand how microRNAs can be modulated to regulate cell functions
Speaker(s)
Overcoming Resistance to Checkpoint Inhibition with Intratumoral or Systemic Injection of a CpG-A TLR9 Agonist
Arthur M. Krieg, MD
Checkmate Pharmaceuticals, United States
CEO and CSO
Antitumoral T-Cell Immunity Triggered by Systemic RNA Lipoplex Vaccination in Cancer Patients
Mathias Vormehr, PhD
BioNTech RNA Pharmaceuticals GmbH, Germany
Head of Cancer Vaccines
Clinical Development of microRNA Inhibitors
Diana Escolar, MD
Miragen, United States
Senior Vice President Medical Science